Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study

This study evaluated the efficacy, safety, and immunogenicity of biosimilar pegfilgrastim (PegFilBS) and originator pegfilgrastim (PegFilOR) in patients with stage 2-4 breast cancer. METHODS: This phase III randomized, multicenter, evaluator-blinded, noninferiority study recruited women with stage 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Kowalyszyn, Ruben D., Fein, Luis E., Richardet, Martin E., Varela, Mirta S., Ortiz, Eduardo, Micheri, Cristian, Zarba, Juan J., Kahl, Susana, Klimovsky, Ezequiel, Federico, Andrea A., Cassini, Jorge H., Cortese, Gustavo, Lago, Nestor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071253/
https://www.ncbi.nlm.nih.gov/pubmed/35324270
http://dx.doi.org/10.1200/GO.21.00276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071253/
https://www.ncbi.nlm.nih.gov/pubmed/35324270
http://dx.doi.org/10.1200/GO.21.00276

Ejemplares similares